Selegiline metabolism and cytochrome P450 enzymes: In vitro study in human liver microsomes

Pharmacology and Toxicology

Volumn 86, Issue 5, 2000, Pages 215-221

  Taavitsainen, Päivi ^a   Anttila, Markku ^b   Nyman, Leena ^b   Karnani, Hari ^b   Salonen, Jarmo S ^b   Pelkonen, Olavi ^a  

^a UNIVERSITY OF OULU   (Finland)

^b ORION CORPORATION   (Finland)

Author keywords

[No Author keywords available]

Indexed keywords

4' HYDROXYMEPHENYTOIN; CHLORZOXAZONE; CYTOCHROME P450; CYTOCHROME P450 2C19; CYTOCHROME P450 3A4; DEXTRORPHAN; DRUG METABOLITE; ETHOXYRESORUFIN DEETHYLASE; FLUVOXAMINE; FURAFYLLINE; HYDROXYTOLBUTAMIDE; KETOCONAZOLE; LIVER ENZYME; MEPHENYTOIN; METHAMPHETAMINE; METHOXSALEN; SELEGILINE;

ARTICLE; CONTROLLED STUDY; DEMETHYLATION; DRUG HYDROXYLATION; DRUG METABOLISM; DRUG POTENCY; ENZYME INHIBITION; HUMAN; HUMAN TISSUE; LIVER MICROSOME; MICHAELIS CONSTANT; PRIORITY JOURNAL;

AMPHETAMINES; ARYL HYDROCARBON HYDROXYLASES; CYTOCHROME P-450 ENZYME SYSTEM; FLUVOXAMINE; HUMANS; KETOCONAZOLE; METHAMPHETAMINE; MICROSOMES, LIVER; MIXED FUNCTION OXYGENASES; MONOAMINE OXIDASE INHIBITORS; SELEGILINE; THEOPHYLLINE;

EID: 0034036617     PISSN: 09019928     EISSN: None     Source Type: Journal    
DOI: 10.1034/j.1600-0773.2000.pto860504.x     Document Type: Article

References (29)

1. Aitio, A.: A simple and sensitive assay of 7-ethoxycoumarin deethylation. Anal. Biochem. 1978, 85, 488-491.
2. Bourrie, M., V. Meunier, Y. Berger & G. Fabre: Cytochrome P450 isoform inhibitors as a tool for the investigation of metabolic reactions catalyzed by human liver microsomes. J. Pharmacol. Exp. Therap. 1996, 277, 321-332.
3. Bradford, M. M.: A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein-dye binding. Anal. Biochem. 1976, 72, 248-254.
4. Burke, M. D., R. A. Prough & R. T. Mayer: Characteristics of a microsomal cytochrome P-448-mediated reaction ethoxy-resorufin O-deethylation. Drug Metab. Dispos. 1977, 5, 1-8.
5. Grace, J. M., M. T. Kinter & T. L. Macdonald: Atypical metabolism of deprenyl and its enantiomer, (S)-(+)-N, α-dimethyl-N-propynylphenethylamine, by cytochrome P450 2D6. Chem. Res. Toxicol. 1994, 7, 286-290.
6. Kashuba, A. D. M., A. N. Nafziger, G. L. Kearns, J. S. Leeder, R. Gotschall, M. L. Rocci, R. W. Kulawy, D. J. Beck & J. S. Bertino: Effect of fluvoxamine therapy on the activities of CYP1A2, CYP2D6, and CYP3A as determined by phenotyping. Clin. Pharmacol. Therap. 1998, 64, 257-268.
7. Knodell, R. G., S. D. Hall, G. R. Wilkinson & F. P. Guengerich: Hepatic metabolism of tolbutamide: Characterization of the form of cytochrome P-450 involved in methyl hydroxylation and relationship to in vivo disposition. J. Pharmacol. Exp. Therap. 1987, 241, 1112-1119.
8. Koller, W. C.: Selegiline monotherapy in the treatment of Parkinson's disease. Neurology 1996, 47, S196-S199.
9. Kronbach, T., D. Mathys, J. Gut, T. Catin & U. A. Meyer: High-performance liquid chromatographic assay for bufuralol l'-hydroxylase, debrisoquine 4-hydroxylase, and dextromethorphan O-demethylase in microsomes and purified cytochrome P-450 isozymes of human liver. Anal. Biochem. 1987, 162, 24-32.
10. Lahtinen, H., J. Koistinaho, R. Kauppinen, A. Haapalinna, R. Keinänen & J. Sivenius: Selegiline treatment after transient global ischemia in gerbils enhances the survival of CA1 pyramidal cells in the hippocampus. Brain Res. 1997, 757, 260-267.
11. Laine, K., M. Anttila, A. Helminen, H. Karnani & R. Huupponen: Dose linearity study of selegiline pharmacokinetics after oral administration: evidence for strong drug interaction with female sex steroids. Brit. J. Clin. Pharmacol. 1999, 47, 249-254.
12. Myllylä, V. V., K. Sotaniemi, O. Mäki-Ikola, U. K. Rinne & E. H. Heinonen: Role of selegiline in combination therapy of Parkinson's disease. Neurology 1996, 47, S200-S209.
13. Mäenpää, J., R. Juvonen, H. Raunio, A. Rautio & O. Pelkonen: Metabolic interactions of methoxsalen and coumarin in humans and mice. Biochem. Pharmacol. 1994, 48, 1363-1369.
14. Nelson, D. R., L. Koymans, T. Kamataki, J. J. Sengeman, R. Feyereisen, D. J. Waxman, M. R. Waterman, O. Gotoh, M. J. Coon, R. W. Estabrook, I. C. Gunsalus & D. W. Nebert: P450 superfamily: update on new sequences, gene mapping, accession numbers and nomenclature. Pharmacogenetics 1996, 6, 1-42.
15. Park, Y. H., M. P. Kullberg & O. N. Hinsvark: Quantitative determination of dextromethorphan and three metabolites in urine by reverse-phase high-performance liquid chromatography. J. Pharmacol. Sci. 1984, 73, 24-29.
16. Pelkonen, O., E. H. Kaltiala, T. K. I. Larmi & N. T. Kärki: Cytochrome P-450-linked monooxygenase system and drug-induced spectral interactions in human liver microsomes. Chem. Biol. Interact. 1974, 9, 205-216.
17. Pelkonen, O., J. Mäenpää, P. Taaritsainen, A. Rantio, H. Raumo: Inhibition and induction of human cytochrome P450 (CYP) enzymes. Xenobiotica 1998, 28, 1203-1253.
18. Peter, R., R. Böcker, P. H. Beaune, M. Iwasaki, F. P. Guengerich & C. S. Yang: Hydroxylation of chlorzoxazone as a specific probe for human liver cytochrome P-450IIE1. Chem. Res. Toxicol. 1990, 3, 566-573.
19. Rasmussen, B. B., T. L. Nielsen & K. Brøsen: Fluvoxamine inhibits the CYP2C19-catalysed metabolism of proguanil in vitro. Eur. J. Clin. Pharmacol. 1998, 54, 735-740.
20. Raunio, H., T. Syngelmä, M. Pasanen, R. Juvonen, P. Honkakoski, M. A. Kairaluoma, E. Sotaniemi, M. A. Lang & O. Pelkonen. Immunochemical and catalytical stucies on hepatic coumarin 7-hydroxylase in man, rat and mouse. Biochem. Pharmacol. 1988, 37, 3889-3895.
21. Raunio, H., J. Valtonen, P. Honkakoski, M. A. Lang, M. Ståhlberg, M. A. Kairaluoma, A. Rautio, M. Pasanen & O. Pelkonen: Immunochemical detection of human liver cytochrome P450 forms related to phenobarbital-inducible forms in the mouse. Biochem. Pharmacol. 1990, 40, 2503-2509.
22. Scheinin, H., M. Anttila, M.-L. Dahl, H. Karnani, L. Nyman, P. Taavitsainen, O. Pelkonen & L. Bertilsson: CYP2D6 polymorphism is not crucial for the disposition of selegiline. Clin. Pharmacol. Therap. 1998, 64, 402-411.
23. Sesardic, D., M. Pasanen, O. Pelkonen & A. R. Boobis: Differential expression and regulation of the members of the cytochrome P450IA gene subfamily in human tissues. Carcinogenesis, 1990, 11, 1183-1188.
24. Shin, H.-S.: Metabolism of selegiline in humans. Identification, excretion, and stereochemistry of urine metabolites. Drug Metab. Dispos. 1997, 25, 657-662.
25. 359 allelic variant in the tolbutamide polymorphism. Pharmacogenetics 1996, 6, 341-349.
26. The Parkinson Study Group: Effects of tocopherol and deprenyl on the progression of disability in early Parkinson's disease. New Engl. J. Med. 1993, 328, 176-183.
27. Wacher, V. J., S. Wong, H. T. Wong & L. Z. Benet: Contribution of CYP3A to selegiline metabolism in rat and human liver microsomes. In: ISSX Proceedings 1996, 10, 351.
28. Waxman, D. J., A. Ko & C. Walsh: Regioselectivity and stereoselectivity of androgen hydroxylations catalyzed by cytochrome P-450 isozymes purified from phenobarbital-induced rat liver. J. Biol. Chem. 1983, 258, 11937-11947.
29. Wrighton, S. A., J. C. Stevens, G. W. Becker & M. VandenBranden: Isolation and characterization of human liver cytochrome P450 2C19: Correlation between 2C19 and S-mephenytoin 4′-hydroxylation. Arch. Biochem. Biophys. 1993, 306, 240-245.